JP2004529911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529911A5 JP2004529911A5 JP2002576189A JP2002576189A JP2004529911A5 JP 2004529911 A5 JP2004529911 A5 JP 2004529911A5 JP 2002576189 A JP2002576189 A JP 2002576189A JP 2002576189 A JP2002576189 A JP 2002576189A JP 2004529911 A5 JP2004529911 A5 JP 2004529911A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- prodrug
- compound
- substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000000651 prodrug Substances 0.000 claims 22
- 229940002612 prodrug Drugs 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 229910004013 NO 2 Inorganic materials 0.000 claims 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- -1 cyano, carboxy Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 102400000068 Angiostatin Human genes 0.000 claims 2
- 108010079709 Angiostatins Proteins 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102400001047 Endostatin Human genes 0.000 claims 2
- 108010079505 Endostatins Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 102000004211 Platelet factor 4 Human genes 0.000 claims 2
- 108090000778 Platelet factor 4 Proteins 0.000 claims 2
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims 2
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000001772 anti-angiogenic effect Effects 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 239000013059 antihormonal agent Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 2
- 229950009003 cilengitide Drugs 0.000 claims 2
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229930014626 natural product Natural products 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229950001248 squalamine Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims 2
- 229960005314 suramin Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940063683 taxotere Drugs 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- 229950000578 vatalanib Drugs 0.000 claims 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000000982 vasogenic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26595101P | 2001-02-02 | 2001-02-02 | |
| PCT/US2002/002888 WO2002076926A1 (en) | 2001-02-02 | 2002-02-01 | 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529911A JP2004529911A (ja) | 2004-09-30 |
| JP2004529911A5 true JP2004529911A5 (enExample) | 2005-12-22 |
Family
ID=23012553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576189A Pending JP2004529911A (ja) | 2001-02-02 | 2002-02-01 | Ｃｘｃケモカインレセプターアンタゴニストとしての３，４−二置換シクロブテン−１，２−ジオン |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20030097004A1 (enExample) |
| EP (1) | EP1355875A1 (enExample) |
| JP (1) | JP2004529911A (enExample) |
| KR (1) | KR20030090629A (enExample) |
| CN (1) | CN1575273A (enExample) |
| AU (1) | AU2002303084B2 (enExample) |
| BR (1) | BR0206968A (enExample) |
| CA (1) | CA2436351A1 (enExample) |
| CZ (1) | CZ20032098A3 (enExample) |
| EC (1) | ECSP034712A (enExample) |
| HU (1) | HUP0304047A2 (enExample) |
| IL (1) | IL156793A0 (enExample) |
| MX (1) | MXPA03006950A (enExample) |
| NO (1) | NO20033424L (enExample) |
| NZ (1) | NZ527947A (enExample) |
| PL (1) | PL367534A1 (enExample) |
| RU (1) | RU2003126913A (enExample) |
| SK (1) | SK9782003A3 (enExample) |
| WO (1) | WO2002076926A1 (enExample) |
| ZA (1) | ZA200305881B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037916B2 (en) * | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7475478B2 (en) | 2001-06-29 | 2009-01-13 | Kva, Inc. | Method for manufacturing automotive structural members |
| MXPA04003439A (es) | 2001-10-12 | 2004-07-08 | Schering Corp | Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc. |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| US20040053953A1 (en) | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
| EP1531827A4 (en) * | 2002-05-24 | 2009-07-08 | Univ Michigan | COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES |
| AU2003242118B2 (en) | 2002-06-06 | 2008-09-11 | Institute Of Medicinal Molecular Design, Inc | O-substituted hydroxyaryl derivatives |
| CN100355423C (zh) * | 2002-06-28 | 2007-12-19 | 诺瓦提斯公司 | 用于治疗肿瘤的包含血管抑制化合物和烷化剂的组合 |
| CN1720240B (zh) * | 2002-10-09 | 2010-10-27 | 先灵公司 | 作为cxc-和cc-趋化因子受体配体的噻二唑二氧化物和噻二唑氧化物 |
| AR041834A1 (es) * | 2002-10-29 | 2005-06-01 | Smithkline Beecham Corp | Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
| EP1562597A4 (en) * | 2002-10-31 | 2008-05-14 | Celgene Corp | COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION AND METHODS OF USE THEREOF |
| WO2004069829A1 (en) * | 2003-01-10 | 2004-08-19 | Pharmacopeia Drug Discovery, Inc. | (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis |
| ATE457307T1 (de) * | 2003-04-18 | 2010-02-15 | Schering Corp | Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid |
| KR20060054308A (ko) * | 2003-07-16 | 2006-05-22 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 피부 색소침착의 치료제 |
| JP4939229B2 (ja) | 2003-12-19 | 2012-05-23 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール |
| WO2005068460A1 (en) * | 2003-12-22 | 2005-07-28 | Schering Corporation | Isothiazole dioxides as cxc- and cc- chemokine receptor ligands |
| MXPA06013118A (es) | 2004-05-12 | 2007-02-28 | Schering Corp | Antagonistas de cxcr1 y cxcr2 de quimocina. |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP2096107A1 (en) | 2004-12-23 | 2009-09-02 | GPC Biotech AG | Derivatives of squaric acid with anti-proliferative activity |
| DE102005001053A1 (de) * | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| CA2600570C (en) * | 2005-03-14 | 2011-12-06 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| CA2613428A1 (en) | 2005-06-29 | 2007-01-11 | Schering Corporation | 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands |
| CN101253165A (zh) | 2005-06-29 | 2008-08-27 | 先灵公司 | 作为cxc－化学活素受体配体的二取代的二唑 |
| DE102005035742A1 (de) * | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| DE102005035741A1 (de) * | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate |
| CN101370775A (zh) | 2006-01-13 | 2009-02-18 | 惠氏公司 | 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚 |
| MY145810A (en) * | 2006-04-21 | 2012-04-30 | Smithkline Beecham Corp | Il-8 receptor antagonists |
| CN101495113A (zh) * | 2006-04-21 | 2009-07-29 | 史密丝克莱恩比彻姆公司 | Il-8受体拮抗剂 |
| MX2008015004A (es) * | 2006-05-26 | 2008-12-05 | Abbott Lab | Inhibidores de cinasas de tipo polo. |
| US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
| AR061571A1 (es) * | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| RU2654068C1 (ru) | 2009-09-28 | 2018-05-16 | Ф.Хоффманн-Ля Рош Аг | Бензоксазепиновые ингибиторы pi3 и способы применения |
| EP2569301A1 (en) | 2010-05-12 | 2013-03-20 | Abbvie Inc. | Indazole inhibitors of kinase |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| JP2020530848A (ja) * | 2017-08-14 | 2020-10-29 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ３，４−二置換３−シクロブテン−１，２−ジオンおよびその使用 |
| MA50424A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 |
| CN108660203A (zh) * | 2018-05-18 | 2018-10-16 | 大连医科大学附属第医院 | Cxcr2基因在心脏相关疾病中的用途 |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1531943A (fr) * | 1966-07-28 | 1968-07-05 | Huels Chemische Werke Ag | Procédé pour stabiliser des poly-acétals macromoléculaires |
| DE2638855C3 (de) * | 1976-08-28 | 1980-04-24 | Chemische Werke Huels Ag, 4370 Marl | Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe |
| US5466712A (en) * | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5849403A (en) * | 1995-09-13 | 1998-12-15 | Kabushiki Kaisha Toshiba | Organic thin film device |
| US6150042A (en) * | 1996-12-09 | 2000-11-21 | Toyo Ink Manufacturing Co., Ltd. | Material for organoelectro-luminescence device and use thereof |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6303238B1 (en) * | 1997-12-01 | 2001-10-16 | The Trustees Of Princeton University | OLEDs doped with phosphorescent compounds |
| JP2998737B2 (ja) * | 1998-03-13 | 2000-01-11 | 日本電気株式会社 | 周辺機器用電源制御装置 |
| US6541129B1 (en) * | 1998-09-09 | 2003-04-01 | Idemitsu Kosan Co., Ltd. | Organic electroluminescence device and phenylenediamine derivative |
| WO2000020378A1 (en) * | 1998-10-02 | 2000-04-13 | Neurosearch A/S | Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| PL348260A1 (en) * | 1998-12-16 | 2002-05-20 | Bayer Ag | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
| JP3924648B2 (ja) * | 1999-11-02 | 2007-06-06 | ソニー株式会社 | 有機電界発光素子 |
| EP1173049B1 (en) * | 2000-02-02 | 2015-05-27 | Mitsubishi Chemical Corporation | Organic electroluminescent element |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| KR20010104215A (ko) * | 2000-05-12 | 2001-11-24 | 야마자끼 순페이 | 발광장치 제작방법 |
| WO2001092202A1 (en) * | 2000-05-30 | 2001-12-06 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| SG138467A1 (en) * | 2000-12-28 | 2008-01-28 | Semiconductor Energy Lab | Luminescent device |
| TW545080B (en) * | 2000-12-28 | 2003-08-01 | Semiconductor Energy Lab | Light emitting device and method of manufacturing the same |
| ES2318003T3 (es) * | 2001-01-16 | 2009-05-01 | Smithkline Beecham Corporation | Antagonistas de los receptores il-8'. |
| TW518909B (en) * | 2001-01-17 | 2003-01-21 | Semiconductor Energy Lab | Luminescent device and method of manufacturing same |
| TW519770B (en) * | 2001-01-18 | 2003-02-01 | Semiconductor Energy Lab | Light emitting device and manufacturing method thereof |
| US6765348B2 (en) * | 2001-01-26 | 2004-07-20 | Xerox Corporation | Electroluminescent devices containing thermal protective layers |
| SG118110A1 (en) * | 2001-02-01 | 2006-01-27 | Semiconductor Energy Lab | Organic light emitting element and display device using the element |
| TWI225312B (en) * | 2001-02-08 | 2004-12-11 | Semiconductor Energy Lab | Light emitting device |
| US20030010288A1 (en) * | 2001-02-08 | 2003-01-16 | Shunpei Yamazaki | Film formation apparatus and film formation method |
| US7432116B2 (en) * | 2001-02-21 | 2008-10-07 | Semiconductor Energy Laboratory Co., Ltd. | Method and apparatus for film deposition |
| SG118118A1 (en) * | 2001-02-22 | 2006-01-27 | Semiconductor Energy Lab | Organic light emitting device and display using the same |
-
2002
- 2002-02-01 PL PL02367534A patent/PL367534A1/xx not_active Application Discontinuation
- 2002-02-01 SK SK978-2003A patent/SK9782003A3/sk not_active Application Discontinuation
- 2002-02-01 US US10/062,006 patent/US20030097004A1/en not_active Abandoned
- 2002-02-01 CZ CZ20032098A patent/CZ20032098A3/cs unknown
- 2002-02-01 EP EP02731085A patent/EP1355875A1/en not_active Withdrawn
- 2002-02-01 JP JP2002576189A patent/JP2004529911A/ja active Pending
- 2002-02-01 CA CA002436351A patent/CA2436351A1/en not_active Abandoned
- 2002-02-01 KR KR10-2003-7009958A patent/KR20030090629A/ko not_active Ceased
- 2002-02-01 MX MXPA03006950A patent/MXPA03006950A/es not_active Application Discontinuation
- 2002-02-01 AU AU2002303084A patent/AU2002303084B2/en not_active Ceased
- 2002-02-01 BR BR0206968-7A patent/BR0206968A/pt not_active IP Right Cessation
- 2002-02-01 CN CNA028045173A patent/CN1575273A/zh active Pending
- 2002-02-01 IL IL15679302A patent/IL156793A0/xx unknown
- 2002-02-01 NZ NZ527947A patent/NZ527947A/en unknown
- 2002-02-01 WO PCT/US2002/002888 patent/WO2002076926A1/en not_active Ceased
- 2002-02-01 RU RU2003126913/04A patent/RU2003126913A/ru not_active Application Discontinuation
- 2002-02-01 HU HU0304047A patent/HUP0304047A2/hu unknown
-
2003
- 2003-07-30 ZA ZA2003/05881A patent/ZA200305881B/en unknown
- 2003-07-31 NO NO20033424A patent/NO20033424L/no not_active Application Discontinuation
- 2003-08-01 EC EC2003004712A patent/ECSP034712A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529911A5 (enExample) | ||
| RU2003126913A (ru) | 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс | |
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| JP2004532846A5 (enExample) | ||
| JP5643312B2 (ja) | カリウムイオンチャネルインヒビターとしてのキナゾリン | |
| JP2020158523A (ja) | 新規ヒストンデアセチラーゼインヒビター | |
| US11690911B2 (en) | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors | |
| JP2016522246A5 (enExample) | ||
| CA2952307A1 (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| JP2019094345A5 (enExample) | ||
| JP2003512353A5 (enExample) | ||
| JP2016505042A5 (enExample) | ||
| CA3082855A1 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists | |
| JP2020527588A5 (enExample) | ||
| JP2004534010A5 (enExample) | ||
| CN116531380A (zh) | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 | |
| JP2008500336A5 (enExample) | ||
| CN102548965A (zh) | 取代酰胺化合物 | |
| JP2019502691A5 (enExample) | ||
| RU2003131693A (ru) | Новые ингибиторы тирозин киназ | |
| CA2543650A1 (en) | A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | |
| JP2017522348A5 (enExample) | ||
| JPWO2008007780A1 (ja) | ペンタジエナミド誘導体 | |
| AU2015338946B2 (en) | Potent gamma-secretase modulators | |
| JP2019505595A5 (enExample) |